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Interrelation of inflammation and APP in sIBM: IL-1b
induces accumulation of b-amyloid in skeletal muscle
Jens Schmidt,1,2 Konstanze Barthel,2 Arne Wrede,3 Mohammad Salajegheh,1 Mathias Ba«hr2 and
Marinos C. Dalakas1,4
1

Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health,
Bethesda, Maryland, USA, 2Department of Neurology and Department of Experimental and Clinical Neuroimmunology,
3
Department of Neuropathology, University of Go«ttingen, Germany and 4Neuromuscular Division, Thomas Jefferson
University Hospital, Philadelphia, Pennsylvania, USA
Correspondence to: Dr Jens Schmidt, Department of Neurology and Department of Experimental and Clinical
Neuroimmunology, University of Go«ttingen, Waldweg 33, 37073 Go«ttingen, Germany, or Dr Marinos Dalakas,
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Distinct interrelationships between inflammation and b-amyloid-associated degeneration, the two major hallmarks of the skeletal muscle pathology in sporadic inclusion body myositis (sIBM), have remained elusive.
Expression of markers relevant for these pathomechanisms were analysed in biopsies of sIBM, polymyositis
(PM), dermatomyositis (DM), dystrophic and non-myopathic muscle as controls, and cultured human myotubes. By quantitative PCR, a higher upregulation was noted for the mRNA-expression of CXCL-9, CCL-3,
CCL- 4, IFN-c,TNF-a and IL-1b in sIBM muscle compared to PM, DM and controls. All inflammatory myopathies
displayed overexpression of degeneration-associated markers, yet only in sIBM, expression of the mRNA of
amyloid precursor protein (APP) significantly and consistently correlated with inflammation in the muscle and
mRNA-levels of chemokines and IFN-c. Only in sIBM, immunohistochemical analysis revealed that inflammatory mediators including IL-1b co-localized to b-amyloid depositions within myofibres. In human myotubes,
exposure to IL-1b caused upregulation of APP with subsequent intracellular aggregation of b-amyloid. Our
data suggest that, in sIBM muscle, production of high amounts of pro-inflammatory mediators specifically
induces b-amyloid-associated degeneration. The observations may help to design targeted treatment strategies
for chronic inflammatory disorders of the skeletal muscle.
Keywords: muscle inflammation; protein aggregation; autoimmunity; b-amyloid; chemokines and cytokines
Abbreviations: APP = amyloid precursor protein; BACE-1 = b-site of APP cleaving enzyme 1; DM = dermatomyositis;
IFN-g = interferon-g; IL-1b = interleukin-1b; IL- 6 = interleukin- 6; MHC class-I = major histocompatibility complex class I;
NCAM = neural cell adhesion molecule; PM = polymyositis; sIBM = sporadic inclusion body myositis; TGF-b = transforming
growth factor-b; TNF-a = tumour necrosis factor-a
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Introduction
Sporadic inclusion body myositis (sIBM) is the most prevalent
myopathy acquired by individuals above 50 years of age. It is a
severely disabling disorder of the skeletal muscle of unknown
cause and no treatment is available (Askanas and Engel, 2006;
Dalakas, 2006). The pathology consists of inflammation
that includes upregulation of proinflammatory chemokines
(De Paepe et al., 2008), most importantly CC- or CXCchemokine ligands (CXCL)-9 (synonym: monokine induced
by interferon-g, MIG) and CXCL-10 (Raju et al., 2003;
De Paepe et al., 2007), CCL-3 (macrophage inflammatory

protein, MIP-1a) (Confalonieri et al., 2000; Civatte et al., 2005)
and CCL-4 (MIP-1b) (Civatte et al., 2005), and cytokines
(Tournadre and Miossec, 2007) such as interleukin (IL)-1b
(Tews and Goebel, 1996; Lundberg et al., 1997) and tumour
necrosis factor (TNF)-a (Tews and Goebel, 1996; Lundberg
et al., 1997; De Bleecker et al., 1999), and transforming growth
factor (TGF)-b (Lundberg et al., 1997). Other inflammatory
mediators including CCL-2 have also been demonstrated to be
crucial during the pathogenesis of inflammatory myopathies
(De Bleecker et al., 2002). In this inflammatory environment,
cytotoxic CD8+ T-cells are attracted to the muscle, where they
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b-amyloid and inflammation in sIBM
clonally expand and attack myofibres that overexpress major
histocompatibility complex (MHC)-class I (Schmidt et al.,
2004; Wiendl et al., 2005). Moreover, the chronic inflammatory environment directly contributes to the damage of muscle
cells as previously demonstrated for IL-1b and TNF-a
(Broussard et al., 2004; Li et al., 2005).
The second hallmark of sIBM is accumulation of
aberrant molecules, most of all b-amyloid, within the
myofibres (Askanas and Engel, 2006). The source of
b-amyloid is amyloid precursor protein (APP) that, when
overexpressed in the muscle of mice, causes muscle
weakness and atrophy (Fukuchi et al., 1998; Jin et al.,
1998; Kitazawa et al., 2006; Sugarman et al., 2006). In vitro,
overexpression of APP and accumulation of b-amyloid
and/or tau protein functionally impairs muscle cells and
induces features similar to myofibres in sIBM, including
formation of vacuoles and intracellular protein aggregates
(Askanas et al., 1996; Christensen et al., 2004).
Accumulations of b-amyloid and even APP are toxic to
the muscle as well as other cells in vivo and in vitro
(Querfurth et al., 2001; Lu et al., 2003). Other cell-stressand degeneration-associated molecules such as the small
heat-shock molecule aB-crystallin and ubiquitin, a tagging
molecule for abnormal proteins, are also overexpressed in
sIBM (Banwell and Engel, 2000). As one possible link
between inflammation and b-amyloid-associated degeneration, IL-1b has been proposed several years ago (Dalakas,
1998; Sondag and Combs, 2004).
To address whether pro-inflammatory and degenerationassociated molecules are unrelated events or trigger each
other in sIBM, we quantified the expression of relevant
molecules in sIBM muscle, arbitrarily selected based on
previous publications and own data (Raju and Dalakas,
2005), and compared their mRNA levels and cellular
localization of the respective protein with those in polymyositis (PM), dermatomyositis (DM) and non-myopathic
control muscles. Using cultures of human myotubes,
we also investigated the expression of inflammatory
chemokines, cytokines and accumulation of b-amyloid
under pro-inflammatory conditions.

Methods
Patients
We investigated the muscle biopsies of patients with sIBM
(n = 12), PM (n = 12), DM (n = 11) or granulomatous myositis
(n = 2), who each fulfilled the clinical, electrophysiological and
histopathological criteria of the respective disease (Dalakas and
Hohlfeld, 2003; Dalakas, 2006); the diagnostic criteria for PM
included a myopathic muscle weakness and electromyogram,
elevated creatine kinase and, on biopsy, a primary endomysial
inflammation with a CD8/MHC-I complex and no rimmed
vacuoles (Dalakas and Hohlfeld, 2003). Control muscle specimens
were obtained from patients with amyotrophic lateral sclerosis
(n = 3), myopathy due to mutations in the b-myosin chain gene
(n = 2), one patient with a genetically defined myofibrillar
myopathy, and six patients with morphologically normal muscle.

Brain (2008), 131, 1228 ^1240

1229

As another control group, six patients with a dystrophic
myopathy, where some secondary inflammation may also exist,
were used. The patients were admitted to the National Institutes
of Health (NIH) Clinical Centre (sIBM, DM, controls), the
University of Göttingen, Germany, (sIBM, PM, controls) and the
Friedrich-Baur-Institute, Muscle Tissue Culture Collection (muscle
dystrophy [MD]-NET, partner of Eurobiobank), in München,
Germany (PM) and studied under Institutional Review Board
(IRB)-approved clinical protocols.

Muscle biopsies and immunohistochemistry
Five-micrometer frozen sections of muscle biopsy specimens were
fixed in 4% paraformaldehyde at room temperature (for
b-amyloid, IFN-g) or acetone at 20 C (all other stainings) for
10 min. Unspecific binding was reduced by 30 min incubation with
5% bovine serum albumin (BSA) and 3% goat or chicken serum
(all from Jackson ImmunoResearch, West Grove, PA) in Tris–
buffered saline (TBS, 0.05 M, pH 7.4, 0.15 M saline). All primary
and secondary reagents were diluted in 1% BSA in TBS.
The primary anti-human antibodies are listed in Table 1.
Immunoreactivity was detected using Alexa-488, Alexa-594 or
Alexa-350-conjugated highly pre-adsorbed secondary goat or
chicken antibodies against mouse, rat, goat or rabbit IgG
(all from Molecular Probes/Invitrogen, Carlsbad, CA). To avoid
cross-reactions in double and triple labelings with primary goat
antibodies, sections were blocked with chicken serum and the
other secondary antibodies were preadsorbed with chicken serum
as previously described (Schmidt et al., 2004). Negative controls
were performed by omission of one of each primary antibody in
every staining. Nuclear counterstaining was performed by DAPI
(Molecular probes/Invitrogen) at 1:50 000 for 1 min, followed
by mounting in Fluoromount G (Electron Microscopy Sciences,
Hatfield, PA, USA). Immunofluorescent microscopy and digital
photography was performed on a Zeiss Axiophot microscope
(Zeiss, Göttingen, Germany), using appropriate filters for green
(488 nm), red (594 nm) and blue (350 nm) fluorescence and a
cooled CCD digital camera (Retiga 1300, Qimaging, Burnaby, BC,
Canada) using the Qcapture software.
For quantitative assessment of immunohistochemical stainings,
grey-scale analysis was performed using the Scion image software
(Scion Image software, Scioncorp., MD, USA). In coded
hematoxylin/eosin sections from all IBM, PM, DM and control
patients, the degree of endomysial inflammation was evaluated
in the entire area of two cross-sections from one biopsy at 100
magnification. Similar to a recent report (Schmidt et al., 2004),
a semi-quantitative grading system ranging from 0 to 3 has been
applied for this purpose with no inflammation (grade 0); mild
inflammation (up to 25% of the biopsy showed invasion by
inflammatory cells: grade 1); moderate inflammation (550% of
the biopsy was invaded by inflammatory cells: grade 2); severe
inflammation (inflammatory cells were present in an area of 50%
and above: grade 3). Each biopsy was evaluated by at least two
independent investigators and a mean grade was calculated.
To quantify stainings for b-amyloid and MHC-I, a mean of 145
muscle fibres per patient were analysed by microscopy and digital
photography by K.B. and Ingrid Müller (University of Göttingen).

Extraction of mRNA and RT-PCR
RT–PCR was performed as previously described (Schmidt et al.,
2004). Total RNA was extracted from muscle biopsies using a kit
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Table 1 List of primary antibodies used for immunohistochemical staining of skeletal muscle biopsy tissue and cultured
muscle cells
Specificity

Host species and clone

Incubation and dilution
or concentration

Supplier

aB-crystallin
APP
b-amyloid
CCL-3
CCL- 4
CXCL-9
Desmin
IFN-g
IL-1b
MHC-I
NCAM
TGF-b
Ubiquitin

Rabbit polyclonal
Goat polyclonal
Mouse clone 6E10
Goat polyclonal
Goat polyclonal
Goat polyclonal
Rabbit polyclonal
Mouse clone 25723
Rabbit polyclonal
Rat clone YTH 862.2
Mouse clone Eric-1
Mouse clone MAB1032
Rabbit polyclonal

1h; 1:1000 dilution
1h; 10 mg/ml
24 h/4 C; 10 mg/ml
24 h/4 C; 20 mg/ml
24 h/4 C; 5 mg/ml
24 h/4 C; 10 mg/ml
1h; 30 mg/ml
24 h/4 C; 5.6 mg/ml
24 h/4 C; 10 mg/ml
1h; 5 mg/ml
1h; 2 mg/ml
1h; 0.5 mg/ml
30 min; 15 mg/ml

Serotec, Oxford, UK
R&D, Minneapolis, MN
Signet, Dedham, MA, USA
R&D
Abcam, Cambridge, MA
R&D
Abcam
R&D
Abcam
Serotec
Labvision/Neomarkers, Fremont, CA
Chemicon, Temecula, CA
DAKO, Carpinteria, CA

(RNeasy from Quiagen, Valencia, CA, USA), following the
supplier’s instructions. In brief, the tissue was homogenized with
a plastic tissue grinder and pestle (Kontes Glass Company,
Vineland, NJ, USA) in 350 ml lysis buffer. RNA was eluted in 30 ml
water and stored at 80 C. cDNA synthesis was performed with
the SuperScript II (Invitrogen) reverse transcriptase, following
the supplier’s instructions. The resulting cDNA was stored
at 20 C. For amplification, 5 ng cDNA was used in a 20 ml
ready-to-use master mix for quantitative (real-time) PCR
(Eurogentec, Serainc, Belgium). Using 6-carboxy-fluorescein
(FAM)-labelled probes and specific primers (Applied Biosystems,
Foster City, CA, USA): Glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Hs99999905_m1); APP (Hs00169098_m1), TGFb1
(Hs00171257_m); IL-1b (Hs00174097_m1); CCL-3 (Hs00234142_
m1); UBB (Hs00430290_m1); CXCL-9 (Hs00171065_m1);
aB-crystallin (Hs00157107_m1); NCAM (Hs00169851_m1);
desmin (Hs00157258_m1); CCL-4 (Hs00605740_g1); IFN-g
(Hs00174143_m1);
TNF-a
(Hs00174128_m1);
IL-6
(Hs00174131_m1). The reactions were run in duplicates on an
Opticon 2 DNA engine (MJ research/Applied Biosystems),
following the standard cycle protocol and instructions given by
the supplier. Target mRNA-expression was quantified using the
c(t) method in relation to expression of GAPDH mRNA. For
all targets with a difference in the duplicate expression of greater
than one c(t), a re-analysis in triplicates was performed. The
quantitative expression analysis of all targets remained within
the linear part of the amplification by PCR.

Cell culture stimulation studies
From diagnostic biopsies of patients without myopathic changes,
muscle cell progenitors (satellite cells) were grown using a
modified protocol (Askanas et al., 1996; Sugiura et al., 2002):
a 3  3  3 mm3 sized piece of muscle was thoroughly minced
using a scissor. After washing in PBS, the muscle was trypsinized
in three subsequent fractions of 15 min. each at 37 C. All
fragments were collected and seeded in a 25 cm2 flask in DMEM
with pyruvate, high glucose and glutamine (Gibco/Invitrogen),
supplemented with 10% FCS (Cambrex Bio Science, Walkersville,
MD, USA), penicillin, streptomycin (all from Gibco/Invitrogen)

and 0.5% chick embryo extract (Accurate chemicals, Westbury,
NY, USA). After two to three subcultures over 2–3 weeks,
myoblasts were labelled with NCAM (anti-CD56, mouse clone
Eric-1, Neomarkers/Labvision, Fremont, CA, USA), magnetic
bead-labelled secondary antibodies and separated by magnets,
following the supplier’s protocol (Dynal/Invitrogen). After expansion during two to three subcultures over 2–3 weeks, myoblasts
were seeded in 8-chamber slides (LabTek II from Nunc, Rochester,
NY, USA) and 24-well plates (Nunc). At 80% confluence, fusion
was induced by switching to DMEM supplemented with 2% horse
serum (Gibco/Invitrogen), penicillin and streptomycin. After 3–5
days, multinucleated myotubes had formed that typically reached
95% purity as revealed by immunohistochemical staining for the
muscle marker desmin. Chamber slides and culture wells in
duplicates were exposed to the cytokines IFN-g (100–1000 U/ml),
TNF-a (1–10 ng/ml), IL-1b (1–20 ng/ml) or TGF-b (1–30 ng/ml)
(all from R&D), alone or in combinations, for 4–72 h in serum
free medium X-vivo 15 (Cambrex Bio Science). Controls were kept
in X-vivo 15 only. After washing in prewarmed PBS, the chamber
slides were fixed in 4% paraformaldehyde (Electron Microscopy
Sciences) at room temperature or in acetone at 20 C and stored
at 80 C until staining (see above). Culture wells were used for
RNA-extraction with subsequent quantitative (real-time) PCR
analysis as described above or protein-extraction with subsequent
Western blot as described below. Secretion of selected cytokines
and chemokines (CCL-3, CXCL-9, IL-1b, TNF-a) was determined
by analysis of the supernatant by multiplexed sandwich ELISA
(Endogen- SearchlightTM proteome array by Pierce Biotechnology,
Woburn, MA, USA).

Western blot
Cells were washed once with cold PBS and lysed in lysis buffer
(20 mM Hepes, 150 mM NaCl, 2 mM EDTA, 1% NP40, pH 7.9)
containing protease inhibitors (complete protease inhibitor cocktail tablets; Roche, Mannheim, Germany). Proteins were separated
by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and transferred to a nitrocellulose membrane (Schleicher &
Schuell, Dassel, Germany). After blocking with 5% skimmed
milk in TBS for 1 h, membranes were incubated over night at 4 C

b-amyloid and inflammation in sIBM
with the primary antibodies anti-APP (rabbit polyclonal antibody
C9, diluted 1:2000, kindly provided by Dennis J. Selkoe, Centre
for Neurologic Diseases, Harvard Medical School and Brigham
and Women’s Hospital, Boston, MA, USA) and anti-b-actin
(mouse monoclonal, diluted 1:1000, Sigma, St Louis, MO, USA).
Horseradish peroxidase-conjugated donkey anti-rabbit and sheep
anti-mouse antibodies (GE Healthcare, Buckinghamshire, UK)
were used as secondary reagents. Blots were developed with
the enhanced chemiluminescence technique (ChemiGlow West;
Alpha Innotech, San Leandro, CA, USA) following the supplier’s
protocol and visualization on X-ray films (Amersham
HyperfilmTMECL; GE Healthcare).

Statistics
For statistical analysis of non-Gaussian distributed mRNAexpression results, the non-parametric Mann–Whitney U-test
and Spearman r-correlation were used. An unpaired t-test was
used for the analysis of all normally distributed results and
Grubb’s test for detection of outliers. All statistics were calculated
using GraphPad Prism V4.0 (San Diego, CA, USA) and P50.05,

P50.01, P50.001 as statistically significant values.

Results
Higher expression of inflammatory
mediators in sIBM compared to PM
and DM muscle
By quantitative (real-time) PCR, the mRNA expression of
key cytokines and chemokines in the muscle biopsies was
compared between non-myopathic controls, sIBM, PM and
DM. Except for IFN-g, present in 4 out 12 samples, a basal
expression of all markers was noted in most non-myopathic
control patients (expression relative to GAPDH; Fig. 1A).
All three chemokines CXCL-9, CCL-4 and CCL-3 were
significantly upregulated in sIBM versus controls by
123–235-fold (Fig. 1B: data indicate the fold- expression
relative to values of controls from Fig. 1A). Their
expression remained clearly lower in PM (31–152-fold; all
significant versus controls; CXCL-9 significant versus DM;
CCL-3 and CCL-4 significant versus sIBM) and DM (14- to
62-fold; all significant versus controls and sIBM; CXCL-9
significant versus PM). By immunohistochemistry, CXCL-9
was widely expressed on the surface of myofibres in sIBM
and, as revealed by double labelling, co-localized and
corresponded well with MHC-I as the standard upregulated
inflammatory marker in myofibres (Fig. 1C). In contrast,
in PM, the signal on myofibres was lower and restricted to
areas of severe inflammation. Immune cells were positive
for CXCL-9 in PM as well as in sIBM. In DM, the signal for
CXCL-9 was much more prevalent in capillaries, immune
cells and connective tissue; only some perifascicular
myofibres, which were also positive for MHC-I, stained
positive for CXCL-9. In non-myopathic control tissue,
staining for CXCL-9 displayed only little signal in some
blood vessels, immune cells and connective tissue (Fig. 1C).
In all three inflammatory myopathies compared to controls,
staining for CCL-3 revealed a very similar pattern as
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for CXCL-9, but remained at a lower level (Fig. 1C).
Immunohistochemical labelling for CCL-4 displayed a
pattern that was essentially identical to CCL-3 (data not
shown).
Expression of mRNA of IFN-g was low in nonmyopathic muscle and drastically upregulated in sIBM by
441-fold, which was significant compared to PM and DM
(Fig. 1B). TNF-a-mRNA was upregulated in PM (26-fold)
and DM (12-fold) compared to controls and much higher
in sIBM (53-fold), which was significant compared to DM.
The mRNA-expression of IL-1b, a cytokine associated with
APP and b-amyloid (Dalakas, 1998; Sondag and Combs,
2004), was significantly upregulated in sIBM versus controls
by 23-fold and remained clearly lower in PM (9.5-fold) and
DM (7.4-fold). By immunohistochemistry in sIBM muscle,
IL-1b was mostly localized to myofibres (Fig. 1C) and
colocalized to MHC-I; some inflammatory cells and the
connective tissue were also positive. In contrast, in PM, the
staining intensity of IL-1b in muscle fibres remained much
lower except for areas of severe inflammation. Unlike in
sIBM, a major part of the signal of IL-1b in PM localized to
immune cells. In DM, IL-1b was almost absent in muscle
fibres and basically restricted to mononuclear cells and
connective tissue (Fig. 1C).
The mRNA-expression of TGF-b was similarly overexpressed in all three inflammatory myopathies by
7–14-fold (Fig. 1B). By immunohistochemistry, TGF-b
was expressed in connective tissue and endomysial
fibroblasts or capillaries in sIBM, PM, DM and dystrophic
myopathies (data not shown), confirming previous
observations (Confalonieri et al., 1997; Amemiya et al.,
2000). The mRNA expression of IL-6 was significantly
augmented in sIBM versus controls by 5-fold, and
DM (4-fold), whereas in PM no change was observed
(Fig. 1B).
Two patients with a granulomatous myositis displayed a
similar mRNA-expression of inflammatory markers compared to PM (data not shown). In dystrophic myopathies,
TGF-b was the only inflammatory mediator that was
significantly upregulated (7-fold, P50.01 versus controls),
but its expression remained significantly lower compared to
sIBM (P50.05) (data not shown).
Collectively, the data show that in sIBM muscle, there is
a much higher upregulation of the mRNA- and proteinexpression of relevant pro-inflammatory chemokines and
cytokines compared to PM and DM. Most importantly,
in sIBM, the pattern of distribution of the chemokines and
IL-1b in the muscle was fundamentally different because
the majority of the inflammatory mediators were abundantly found in the myofibres, whereas in PM, a lower
expression was observed with a restriction to areas of severe
inflammation. In DM, the pro-inflammatory molecules
were mainly localized to the connective tissue and
capillaries and only to a minor degree in some perifascicular areas.
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Fig. 1 Quantification and localization of pro-inflammatory markers in sIBM compared to PM, DM and non-myopathic control muscle.
(A) GAPDH-normalized mRNA expression of pro-inflammatory and degeneration-associated markers amplified by quantitative (real-time)
PCR from skeletal muscle tissue of non-myopathic control patients (n = 12). Each dot represents one patient with arbitrary units multiplied by
1000. (B) GAPDH-normalized mRNA expression of pro-inflammatory markers amplified by quantitative PCR from skeletal muscle tissue of
sIBM patients (n = 12, red spades), PM (n = 12, blue circles) and DM (n = 11, green triangles). Data are expressed as fold-expression in relation to
values from (A) in non-myopathic controlmuscle.Each dotrepresents one patient. Statistics were performed as detailedin the Methods section
using P50.05, P50.01, P50.001as significant values.Undetectable values are not plotted on the logarithmic scale of the y-axis.
(C) Fluorescent double-labelling (MHC-I and CXCL-9) and single-labelling (CCL-3, IL-1b) immunohistochemistry in representative muscle
biopsy specimens of sIBM versus PM, DM and non-myopathic muscle, using antibodies for MHC-I (top row),CXCL-9 (second row),CCL-3 (third
row) or IL-1b (bottom row) with Alexa-594 (red) or Alexa-488 (green)-labelled secondary antibodies and DAPI-counterstain (blue). Arrows
in sIBM denote myofibres that display overexpression of IL-1bor co-expression of MHC-I,CXCL-9 and CCL-3. In PM, arrows indicate myofibres
that are localized in areas of inflammation and show an enhanced staining signal of MHC-I,CXCL-9,CCL-3 or IL-1b; arrowheads point to mononuclear cells that express CXCL-9,CCL-3 or IL-1b. In DM, arrows indicate muscle fibres that are located in the perifascicular area and display an
enhanced staining signal of MHC-I,CXCL-9,CCL-3 or IL-1b; stars indicate upregulation of MHC-I,CXCL-9 and CCL-3 in capillaries; arrowheads
denote connective tissue positive for MHC-I,CXCL-9 or CCL-3 as well as mononuclear cells positive for IL-1b. Photos taken by a CCD-camera
using a conventional fluorescent microscope with a10 objective. Scale bars represent100 mm in rows1^3 and 50 mm in the last row.

b-amyloid and inflammation in sIBM
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Fig. 2 Quantification and localization of degeneration-associated markers in sIBM compared to PM, DM and non-myopathic control
muscle. (A) By quantitative (real-time) PCR from muscle tissue, an overexpression of the mRNA of the degenerative markers APP, desmin,
NCAM, ubiquitin and aB-crystallin was observed in sIBM, PM and DM compared to non-myopathic controls. Symbols, analysis, statistics
and plotting same as in Fig. 1B. (B) Fluorescent immunohistochemistry in representative muscle biopsy specimens of sIBM versus PM, DM
and non-myopathic muscle, using an antibody for APP and an Alexa-594 (red)-labelled secondary antibody. Arrows point to muscle fibres
that display overexpression of APP in sIBM, PM or DM (perifascicularly). Arrowheads denote an enhanced staining signal for APP in
connective tissue in DM. The star indicates an upregulated expression of APP in capillaries of DM muscle. Photos taken by a CCD-camera
using a conventional fluorescent microscope with a 20 objective. Scale bar represents 50 mm.

Upregulation of degeneration-associated
molecules in sIBM, PM and DM muscle
The mRNA levels of degeneration-associated molecules
were analysed by quantitative (real-time) PCR in the muscle
biopsies of sIBM, PM, DM and controls. Except for NCAM,
which was detectable in 5 out of 12 samples, a baseline
expression of all markers was present in all non-myopathic
control patients (expression relative to GAPDH; Fig. 1A).
In sIBM versus controls, there was a significant upregulation of APP, ubiquitin and the heat-shock protein
aB-crystallin (Fig. 2A: data indicate the fold- expression
relative to values in controls from Fig. 1A). These molecules
were similarly upregulated in DM and PM, although—due
to a higher variability—not statistically significant in PM,
except for APP. Surprisingly, APP was expressed even
higher in DM than in sIBM. Desmin was similarly and
significantly upregulated in sIBM and DM; the expression
level in PM was similar, yet remained statistically insignificant due to a higher variability. The mRNA-expression
of NCAM was elevated in sIBM, which was significant
compared to controls, and DM, which was significant

compared to controls and PM. These data suggest that
the noted changes were not related to major differential
effects on degenerative/regenerative fibres. None of the
degeneration-associated markers was significantly upregulated in a group of six patients with dystrophic myopathies
(data not shown).
Despite a similar upregulation of the mRNA of all the
aforementioned molecules in all three inflammatory
myopathies, immunohistochemical analysis revealed striking differences of the staining pattern of APP (Fig. 2B).
In sIBM, the vast majority of the staining signal of
APP derived from a remarkable overexpression in a large
fraction of muscle fibres. By contrast, in PM, a much lower
expression was observed, which was more pronounced in
myofibres of areas with severe inflammation. In DM, most
of the signal localized to inflammatory cells, connective
tissue, vessels and only some myofibres in the perifascicular
regions (Fig. 2B). In some fibres of sIBM but not PM and
DM muscle, ubiquitin was co-expressed with b-amyloid
(data not shown).
Many muscle fibres in sIBM were double positive for
NCAM and desmin, many of which were also positive
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for aB-crystallin (data not shown). In PM, a similar
distribution of these markers was observed only in some of
the cases. In contrast, in DM, muscle fibres that overexpressed NCAM, aB-crystallin, MHC-I or desmin were
restricted to the perifascicular region (data not shown).
Collectively, these data show that, in sIBM, degenerationassociated molecules were overexpressed at the level of
mRNA and protein. A co-localization of several of these
molecules could be demonstrated by immunohistochemistry. To the contrary, in PM the mRNA-expression of
degeneration-associated molecules was much more variable
and the protein expression lower compared to sIBM.
In DM, most of the signal of APP was localized to the
connective tissue and capillaries, but only some myofibres
in the perifascicular areas.

b-amyloid and APP correlate with expression
of inflammatory molecules in sIBM in
contrast to PM and DM
As expected, the mRNA expression of ubiquitin correlated
with the expression of APP in sIBM (data not shown).
Strikingly, in sIBM, but not in PM and DM, the mRNA
expression of APP was significantly associated with the
grade of the cellular infiltration as assessed by semiquantitative grading of H&E staining (Fig. 3A). Furthermore,
in sIBM but not in DM or PM, the mRNA-expression of
APP significantly correlated with the mRNA-expression
of CXCL-9 and IFN-g (Fig. 3A) as well as CCL-3 (Pearson
r = 0.6; P50.05) and CCL-4 (Pearson r = 0.7; P50.05)
(data not shown). In sIBM compared to PM and DM,
a closer association between the mRNA-expression of IL-1b
and APP was observed (Fig. 3A). The other cytokines
TNF-a and IL-6 did not correlate with the mRNAexpression of APP in sIBM (data not shown). By Grubb’s
test of mRNA-expression levels, outliers in the groups of
PM and DM were statistically identified, while in the IBM
group no outliers were detected. Whereas the majority of
PM and DM patients had a short history of clinical
symptoms for less than one year, three patients in each
group had a longer disease course: 4, 7 and 10 years in the
PM group and 45, 2 and 3 years in DM. Outlier patients
with a high expression of APP had a relatively long disease
course (7 years in PM and 3 years in DM). In contrast,
patients with a high grade of inflammation—and a
relatively low expression of APP—had presented with a
short, but very severe course of the disease. After removal
of outliers, there was a significant correlation in the group
of PM-patients between the mRNA-expression of APP and
the grade of inflammation and the mRNA-expression of
IL-1b. All other correlations in PM as well as in DM
remained insignificant (Supplementary Fig. 1). In line with
the lack of overexpression of pro-inflammatory mediators
except TGF-b, there was no detectable cellular inflammation in the group of patients with a dystrophic myopathy.
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Double-labelling
fluorescent
immunohistochemistry
further corroborated these associations on a cellular
level. In sIBM, b-amyloid was present in 15.3  3.7%
(mean  SEM) of the muscle fibres. Almost all b-amyloidpositive fibres expressed MHC-I and often represented the
population of the brightest MHC-I expressing fibres
(Fig. 3B). In PM and DM, no such accumulation of
b-amyloid was observed (data not shown).
Collectively, these findings indicate that a distinct
relationship between b-amyloid-associated markers and
the expression of inflammatory mediators was mainly
observed in sIBM muscle compared to PM and absent
in DM.

Human muscle cells in vitro display molecular
mechanisms of chronic muscle inflammation
To address a possible interrelationship between inflammation and b-amyloid-associated degeneration in normal
skeletal muscle in vitro, we established cultures of 95%
pure myotubes from biopsies of non-myopathic individuals
(Fig. 4A). Under normal cell culture conditions, myotubes
did not express detectable levels of mRNA-expression of
CXCL-9, CCL-3, CCL-4 or TNF-a, but baseline levels of
IL-6 and IL-1b (Fig. 4B and C). In pilot experiments, the
response to cytokine-stimulation was evaluated by comparing effects of IFN-g (100–1000 U/ml), TNF-a (1–10 ng/ml),
IL-1b (1–20 ng/ml) and TGF-b (1–30 ng/ml) for 4 h up to
48 h (data not shown). After 24 h of exposure to IFN-g
(300 U/ml), TNF-a (5 ng/ml), IL-1b (10 ng/ml), alone or in
combination, there was a striking upregulation of the
mRNA expression of CXCL-9, CCL-3, CCL-4, IL-6 and
IL-1b, particularly after combinations of IFN-g with IL-1b
(Fig. 4B and C). TNF-a expression in myotubes was
upregulated after TNF-a alone or in combination with
IFN-g or IL-1b as well as by IFN-g and IL-1b, which
displayed a synergistic effect on the TNF-a expression.
Most importantly, the striking upregulation of IL-1b in
response to various pro-inflammatory stimuli, including a
feed-forward amplification, is explained by an upregulation
of the IL-1b receptor (Adams et al., 2002) and is consistent
with previous reports (Nagaraju et al., 1998). Particularly
this synergism between IFN-g and IL-1b may be crucial
for a cell-stress response inflicted by conditions of a
severe inflammation that correlates with accumulation
of b-amyloid in sIBM as shown above and previously
suggested (Dalakas, 1998; Sondag and Combs, 2004).
Respective protein expression of CCL-3, CXCL-9, IL-1b
and TNF-a by myotubes upon exposure to IL-1b, IFN-g,
TNF-a, alone or in combination, was confirmed by analysis
of the supernatant by ELISA (data not shown).
Taken together, we showed that, upon stimulation with
high concentrations of cytokines, particularly a combination
of IFN-g and IL-1b, differentiated human myotubes displayed
a striking expression of chemokines and cytokines including
an auto-amplificatory overexpression of IL-1b. The pattern of
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Fig. 3 Correlation of the mRNA- and protein-expression (same mRNA-data as shown in Figs1and 2) of b-amyloid-associated and
inflammatory markers in the muscle of sIBM, PM and DM patients. (A) Correlation of the mRNA-expression of APP with the grade of cellular
infiltration as assessed by H&E staining (first column), the mRNA-expression of CXCL-9 (second column), IFN-g (third column) as well as with
IL-1b (last column).One dot per patient. Due to similar values, two patients in the PM group are plotted with a high degree of overlap.
(B) Immunohistochemical double labelling for b-amyloid (Alexa-594; red) and MHC-I (Alexa-488; green) reveals a frequent co-localization
(arrows) of these markers in myofibres in a representative muscle biopsy specimen of a patient with sIBM. Nuclear counterstain with DAPI.
Images taken by a CCD-camera using a conventional fluorescent microscope with a 20 objective. Scale bar represents 50 mm.

expression of the pro-inflammatory mediators appeared
similar to what was observed in myofibres of sIBM muscle
and confirmed the inherent ability of the muscle to produce
inflammatory cytokines under pro-inflammatory conditions.

IL-1b augments accumulation of b-amyloid
in human skeletal muscle cell cultures and
co-localizes to b-amyloid in sIBM muscle
To test the hypothesis that a severe inflammation would
trigger or augment accumulation of b-amyloid, myotubes

were exposed to the amyloidogenic cytokine IL-1b, alone
or in combination with IFN-g. After 24 h, IL-1b, alone or
in combination with IFN-g, significantly upregulated the
protein expression of APP as revealed by immunocytochemistry (Fig. 5A). Consistent with this, an upregulation
of APP was observed by immunoblot analysis after
exposure to IL-1b and IFN-g for 24–72 h (Fig. 5B). After
48 h, IL-b, and more so IL-1b in combination with IFN-g,
significantly augmented intracellular staining for b-amyloid
(Fig. 5C). Forty-eight hours after cytokine exposure,
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A

B

C

Fig. 4 In vitro analysis of expression of pro-inflammatory mediators in primary cultures of differentiated human myotubes. (A) Purity of
primary myotube cultures was assessed by immunohistochemical staining of the muscle cell marker desmin (Alexa-488; green) with a
typical purity of 95% as revealed by comparison to phase contrast photos of the same culture well. Scale bar represents 100 mm. (B and C)
mRNA-expression relative to GAPDH of chemokines (B) and cytokines (C) as assessed by quantitative (real-time) PCR in myotubes
exposed 24 h to IFN-g (300 U/ml), TNF-a (5 ng/ml) or IL-1b (10 ng/ml)çalone or in combinations. Data are given as mean + SD of two wells
per condition from one representative experiment of four with similar results.

the enhanced immuno-labelling for b-amyloid was accompanied by significant protein aggregation as indicated by
thioflavin-S cytochemistry (Fig. 5D). This intracellular
accumulation of b-amyloid further increased after 72 h
and was associated with degeneration of the myotubes (data
not shown).
The in vitro association between inflammatory cytokines and b-amyloid was further substantiated by a
co-localization of b-amyloid and IL-1b only in sIBM
muscle (Fig. 6), which is in line with a previous observation
(Dalakas, 1998) and was not present in DM or PM as
reconfirmed in the present study.
Collectively, IL-1b, particularly in combination with
IFN-g, induced an overexpression of APP at the protein
level in human myotubes. Subsequently, an enhanced
b-amyloid staining and thioflavin-S positive aggregations of
protein were observed. This suggests a direct contribution

of IL-1b to the generation of intracellular accumulation of
b-amyloid in human muscle cell culture.

Discussion
We here demonstrate that highly upregulated proinflammatory cytokines and chemokines in sIBM muscle correlate
and co-localize with the expression of b-amyloid-associated
proteins. In contrast to PM and DM, the other two
inflammatory myopathies used as comparative controls, in
sIBM, the majority of the signal for inflammatory and
degenerative markers localized strongly to muscle fibres.
In PM, the expression level remained lower and limited to
chemokines and IL-1b, which mainly localized to myofibres
next to areas of severe inflammation; in contrast, these
markers were widespread in myofibres of sIBM muscle.
In DM, the expression remained much lower and was
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Fig. 5 Overexpression of APP and accumulation of b-amyloid in human primary skeletal myotube cultures exposed to IL-1b (10 ng/ml)
and/or IFN-g (300 U/ml) for 24 ^72 h. (A) A 24 h exposure to IL-1b, alone or in combination with IFN-g, induced enhanced staining for APP
(Alexa-594, red). Grey-scale analysis of the same experiment demonstrates a significant increase of the staining intensity upon IL-1b, and
even more in combination with IFN-g. (B) Immunoblot analysis of APP demonstrates an increased level of protein expression upon 24 ^72 h
of exposure to IL-1b in combination with IFN-g. Protein loading in each lane is confirmed by detection of b-actin. (C) Staining for b-amyloid
reveals an enhanced intracellular accumulation upon 48 h of exposure to IL-1b, particularly in combination with IFN-g (Alexa-488, green).
Grey-scale analysis of the same experiment demonstrates a significant increase of the staining intensity upon IL-1b, and even more in
combination with IFN-g. (D) After 48 h of exposure to IL-1b and IFN-g, intracellular aggregation of b-amyloid is evidenced by thioflavin-S,
which is statistically significant as revealed by grey-scale analysis of the same experiment. Photos taken by a CCD-camera using a conventional fluorescent microscope with a 10 (A and C) or 20 (D) objective. All photomicrographs for the analyses in this Figure have been
acquired with the same settings of camera and microscope; all data are representative of at least three experiments with similar results.
Scale bars represent 100 mm in A, C and 60 mm in D.
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Fig. 6 Fluorescent immunohistochemical double labelling for b-amyloid and IL-1b. Representative muscle biopsy specimen of a patient
with sIBM stained with anti-b-amyloid (Alexa-488, green; left) and anti-IL-1b (Alexa-594, red; middle). A degenerating muscle fibre in the
centre is double positive (arrows; yellow in merged image, right). Photos taken by a CCD camera using a conventional fluorescent
microscope with a 40 objective. Scale bar represents 40 mm.

predominantly observed in blood vessels and connective
tissue. Under inflammatory conditions, purified human
myotube cultures displayed a similar pattern of expression
of pro-inflammatory cytokines and chemokines, including
an auto-amplificatory upregulation of IL-1b. Exposure of
myotubes to IL-1b, particularly in combination with
IFN-g, induced an overexpression of APP with subsequent
intracellular accumulation of b-amyloid and protein
aggregation.
Overexpression of the mRNA or protein of proinflammatory chemokines and cytokines in sIBM muscle
was in line with previous observations for CXCL-9 (Raju
et al., 2003), CCL-3 (Confalonieri et al., 2000) and CCL-4
(Civatte et al., 2005), and the cytokines IFN-g, TNF-a and
IL-1b (Tews and Goebel, 1996); moreover, the chemokines
and IL-1b localized to muscle fibres. In contrast, in PM,
the expression was lower and restricted to areas of severe
inflammation. In DM, the expression was much less and
mostly confined to the connective tissue. This is consistent
with previous observations that myofibres in sIBM as
well as muscle cells—upon pro-inflammatory stimulation
in vitro—produce large amounts of these mediators
(Nagaraju et al., 1998; Raju et al., 2003), which contribute
to the infiltration of muscle fibres by immune cells or even
to their local activation (Schmidt et al., 2004; Wiendl et al.,
2005). Given the similar magnitude of upregulation of the
degeneration-associated molecules including APP, ubiquitin, desmin and aB-crystallin that we observed in all three
inflammatory myopathies, one could argue that a chronic
inflammation in muscle always results in overexpression of
pathways associated with degenerative pathomechanisms.
In line with this, a high expression of the mRNA of APP
was noted in patients with a chronic disease course of DM
or PM. However, only in sIBM, there was a significant and
consistent correlation between the mRNA expression of
b-amyloid-associated molecules and the major inflammatory markers. Moreover, only in sIBM, the inflammatory
molecules CXCL-9, MHC-I and IL-1b co-localized with
APP and b-amyloid within the fibres, which suggests some

association between inflammation and degeneration in
sIBM muscle. It is conceivable that a so far unknown
underlying condition in sIBM may cause a higher baseline
expression of APP as well as its extensive upregulation
under inflammatory conditions. An increased generation of
b-amyloid may be due to alterations of the processing of
APP via b-site of APP cleaving enzyme (BACE)-1 (Vattemi
et al., 2001) or macroautophagy (Lunemann et al., 2007).
Moreover, muscle fibres in sIBM may be susceptible even to
weak inflammatory stimuli and readily respond with a
chronic auto-amplificatory production of chemokines and
cytokines. Lastly, mechanisms that protect from intracellular cell-stress inflicted by inflammation or accumulation
of b-amyloid may be insufficiently present in sIBM.
It is conceivable that a particularly low grade of
inflammation and an unusual disease course in some
PM patients might have been responsible for the lower
expression levels of inflammatory mediators and an outlier
with a high APP-mRNA expression compared to IBM and,
thus, biased parts of the results. However, in patients with
low as well as a more severe inflammation, immunohistochemical analysis revealed a fundamentally different pattern
of distribution of these markers: In PM, only some muscle
fibres next to the areas of intense inflammation displayed
a focal staining signal, while in DM the expression
predominantly localized to blood vessels, capillaries and
connective tissue. In contrast, independent of the grade of
cellular inflammation in sIBM muscle, there was a widespread labelling of the muscle fibres and some minor
staining of connective tissue. Collectively, we surmise that
the most likely reasons for inflammation to cause chronic
degenerative damage of muscle fibres in sIBM—as opposed
to PM and DM—are due to (i) the magnitude of the
production of pro-inflammatory mediators and their
chronic, auto-amplificatory augmentation and (ii) the
predominant localization of the inflammatory stressors
within the muscle fibres themselves. Particularly in DM,
inflammatory mediators localized to small vessels, connective tissue and slightly the perifascicular regions
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(areas with the most significant cell-stress response), but
not to the muscle fibres as seen in sIBM. The grade of
expression of the mRNA of APP was even higher in DM
than in sIBM. Since APP is considered to be among the
acute phase proteins (Gitter et al., 2000) and is upregulated
in vitro upon stimulation by inflammatory cytokines as
demonstrated by our results, it is conceivable that a similar
mechanism of induction of overexpression of APP is
active on the level of blood vessels and connective tissue.
The differential response by muscle fibres in sIBM
compared to blood vessels in DM may be explained by
a higher local concentration of inflammatory mediators
produced by the muscle fibres themselves in sIBM instead
of blood vessels and connective tissue in DM. In PM, some
myofibres expressed chemokines and IL-1b, but the levels
remained much lower compared to sIBM and restricted to
fibres of areas with severe inflammation. Consistent with
this interpretation, our data showed that a prolonged
exposure of muscle cells to high concentrations of
pro-inflammatory cytokines induced b-amyloid-associated
degeneration.
High concentrations of cytokines and chemokines can be
directly detrimental to muscle cells as previously demonstrated for IL-1b (Broussard et al., 2004) and TNF-a
(Li et al., 2005). Furthermore, direct toxicity of APP or
accumulation of b-amyloid may contribute to muscle cell
damage in vitro and in vivo (Askanas et al., 1996; Fukuchi
et al., 1998; Jin et al., 1998; Querfurth et al., 2001;
Christensen et al., 2004; Kitazawa et al., 2006; Sugarman
et al., 2006). However, inflammation could also augment
processing of APP through upregulation of BACE-1, as
recently observed in astrocytes upon IFN-g (Hong et al.,
2003). On the other hand, b-amyloid induces upregulation
of various cytokines in vitro (Franciosi et al., 2005) and an
association between b-amyloid and inflammation has been
noted in human AD and in its mouse model (Fonseca
et al., 2004). Such a bi-directional augmentation between
APP and IL-1b has recently been demonstrated (Sondag
and Combs, 2004) and suggested almost a decade ago
(Dalakas, 1998). As another inflammatory-degenerative
association in muscle cells, an increased production of
nitric oxide has been demonstrated after combined
exposure to b-amyloid and IFN-g (Baron et al., 2000).
Collectively, it appears that in sIBM, inflammatory and
degenerative mechanisms act in concert to exert toxicity.
But in spite of the evidence that cytokines and APP/
b-amyloid augment each other, it remains unclear if the
triggering factor in sIBM is the inflammation or the
accumulation of b-amyloid.
In summary, our data demonstrate a striking upregulation of inflammatory chemokines and cytokines in sIBM
muscle and a specific interplay between inflammatory and
b-amyloid-associated pathomechanisms. Ubiquitous upregulation of IL-1b in muscle fibres may aggravate an
overexpression of APP and lead to an accumulation of
b-amyloid. The data further our understanding of the
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pathology not only of sIBM, but also of other neuroinflammatory and neurodegenerative conditions where
interactions between inflammation and accumulation of
b-amyloid contribute to the pathology.

Supplementary material
Supplementary material is available at Brain online.
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